Opus Genetics is trading 5.06% lower at $3.85, despite positive clinical findings across its OPGx-BEST1 and OPGx-LCA5 programs. - OPGx-BEST1 showed improved retinal sensitivity in three of four evaluable low-dose participants. - OPGx-LCA5 participants showed sustained visual-function gains. - The biotech sector is also under pressure, with XBI down 2.06%; this is consistent with the stock’s decline, but available evidence does not establish a direct cause.